BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Rapamycin
1
Rapamycin suppresses small bowel adenocarcinoma HUTU 80 cells proliferation by inhibiting hypoxia-inducible factor-1α mediated metabolic reprogramming
9/15/2025 8:38:08 AM | Browse: 359 | Download: 304
2
Effect of rapamycin nanoparticles in an animal model of primary biliary cholangitis
6/26/2025 7:27:54 AM | Browse: 120 | Download: 758
3
Real-world five-year outcomes of FlexyRap® cobalt-chromium rapamycin-eluting stents with biodegradable polymer in patients with de-novo coronary artery disease
3/21/2023 6:10:46 AM | Browse: 389 | Download: 1450
4
Sirolimus vs tacrolimus: Which one is the best therapeutic option for patients undergoing liver transplantation for hepatocellular carcinoma?
8/24/2022 11:31:49 AM | Browse: 601 | Download: 1054
5
Trends of rapamycin in survival benefits of liver transplantation for hepatocellular carcinoma
9/18/2021 1:32:04 PM | Browse: 572 | Download: 1521
6
Sirolimus treatment for neonate with blue rubber bleb nevus syndrome: A case report
8/5/2021 2:37:06 PM | Browse: 527 | Download: 1481
7
Delayed and short course of rapamycin prevents organ rejection after allogeneic liver transplantation in rats
10/16/2017 7:24:27 AM | Browse: 1127 | Download: 2042
8
Contribution of mammalian target of rapamycin in the pathophysiology of cirrhotic cardiomyopathy
5/19/2016 9:54:00 AM | Browse: 721 | Download: 2235
9
Immunosuppressive potency of mechanistic target of rapamycin inhibitors in solid-organ transplantation
3/18/2016 2:28:00 PM | Browse: 1355 | Download: 2262
10
mTOR signaling in liver regeneration: Rapamycin combined with growth factor treatment
9/15/2014 9:08:00 AM | Browse: 1296 | Download: 1223
11
Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients
8/25/2014 9:54:00 AM | Browse: 1091 | Download: 1475
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345